| 1.99 0.02 (1.02%) | 10-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.53 | 1-year : | 2.74 |
| Resists | First : | 2.17 | Second : | 2.34 |
| Pivot price | 2.11  |
|||
| Supports | First : | 1.88 | Second : | 1.57 |
| MAs | MA(5) : | 2.01 |
MA(20) : | 2.1 |
| MA(100) : | 2.19 |
MA(250) : | 2.33 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 3.9 |
D(3) : | 7.4 |
| RSI | RSI(14): 37.1  |
|||
| 52-week | High : | 3.06 | Low : | 1.79 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AYTU ] has closed above bottom band by 20.7%. Bollinger Bands are 38.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.03 - 2.04 | 2.04 - 2.05 |
| Low: | 1.94 - 1.95 | 1.95 - 1.97 |
| Close: | 1.97 - 1.99 | 1.99 - 2.01 |
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
Wed, 07 Oct 2026
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy? - The Globe and Mail
Thu, 01 Oct 2026
Aytu Biopharma Inc (AYTU-Q) Stock Price and News - The Globe and Mail
Wed, 30 Sep 2026
Aytu BioPharma (NasdaqCM:AYTU) Stock Forecast & Analyst Predictions - Simply Wall Street
Wed, 23 Sep 2026
Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EXXUA Launch Accelerates as ... - Yahoo Finance
Tue, 22 Sep 2026
Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView
Tue, 22 Sep 2026
Aytu BioPharma reports FY2026 revenue $57.6M, Q4 revenue $16.1M and Adjusted EBITDA $0.5M - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 11 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 8.1 (%) |
| Held by Institutions | 35.5 (%) |
| Shares Short | 345 (K) |
| Shares Short P.Month | 334 (K) |
| EPS | -1.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.28 |
| Profit Margin | -24.8 % |
| Operating Margin | -4.9 % |
| Return on Assets (ttm) | -4.6 % |
| Return on Equity (ttm) | -52.6 % |
| Qtrly Rev. Growth | 6.4 % |
| Gross Profit (p.s.) | 3.38 |
| Sales Per Share | 5.29 |
| EBITDA (p.s.) | -0.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -1.72 |
| PEG Ratio | 0 |
| Price to Book value | 0.6 |
| Price to Sales | 0.37 |
| Price to Cash Flow | 6.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|